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cIn the development trajectory of a new noninvasive
imaging agent or technology, initial studies often
focus on the ability of the modality to detect or rule
out coronary disease, driven in part by regulatory
considerations because regulatory approval often
involves measures of diagnostic performance. Later
in the life cycle of the modality, studies begin to
appear that evaluate the prognostic performance of
the technique.
See page 1014
The seminal studies of Brown et al. (1) and
Ladenheim et al. (2) in the 1980s brought to the
fore the concept of using noninvasive imaging data
to assess prognosis. Since that time, there have been
literally hundreds, if not thousands, of publications
evaluating the prognostic implications of imaging
findings. These papers span the gamut of all imag-
ing modalities, as well as spanning across distinct
techniques and patient groups within modalities.
For example, the prognostic ability of radionuclide
myocardial perfusion imaging (MPI) seems to hold
no matter what tracer or stressor is used and seems
to hold across both genders (3).
After those initial reports involving radionuclide
imaging, the literature grew over the subsequent 15
years. In 2003, the American College of Cardiolo-
gy/American Heart Association/American Society
for Nuclear Cardiology guidelines for radionuclide
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atients in which a normal stress myocardial perfu-
ion study was associated with a subsequent event
ate of 1% per year (3). In contemporary practice,
he expectation of the community for such data has
rown, and the speed with which data are gathered
nd published has increased as well. Relatively soon
fter multidetector computed tomography angiog-
aphy (CTA) reached a stage in its technical devel-
pment allowing widespread use and good diagnos-
ic performance, multicenter studies involving
20,000 patients appeared documenting the prog-
ostic power of this modality (4).
The general concepts involved in the literature in
his area follow a stereotypical format. Some mea-
ure of the magnitude of abnormality of the imag-
ng data is related to the risk of an untoward event
ver long-term follow-up. In the radionuclide MPI
iterature, this usually means that a semiquantitative
r quantitative measure of the extent and/or severity
f perfusion abnormality on the stress image relates
o the risk of cardiac death or nonfatal myocardial
nfarction during follow-up. The more abnormal
he perfusion during the test, the higher the risk
usually annualized) of a subsequent event (1,2).
he abnormality on imaging could be the extent of
all motion abnormality on stress echocardiogra-
hy (5), abnormal perfusion on stress cardiac mag-
etic resonance (6), or the extent of coronary
isease on CTA (4).
A consistently important feature of all of these
tudies is the low event rate associated with a
ormal study result. As noted, this has been well
ocumented for radionuclide MPI (3), for CTA
7), and indeed for all of the modalities, although
ess overall information exists at this time point for
ardiac magnetic resonance. The reason such infor-
ation is important clinically is that among all
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 1 0 , 2 0 1 2
O C T O B E R 2 0 1 2 : 1 0 2 2 – 4
Udelson
Editorial Comment
1023outpatients referred for noninvasive testing, the
majority will have a normal study result. Knowing
that this result is associated with very low risk assists
clinicians in making a decision toward a conserva-
tive management strategy.
What underlies this consistent finding in the
literature? Of course, many patients have normal
study results because they do not have underlying
coronary disease and thus are not at risk for cardiac
events over the foreseeable future. However, the
data showing that outcomes associated with a nor-
mal study are also relatively benign even among
patients with known coronary disease (8) have
suggested that the demonstration of normal stress
perfusion is likely reflective of other factors that
influence myocardial blood flow, such as preserved
endothelial function and robust collateralization,
which should also be protective against acute
events. Thus, there are many reasons why clinicians
desire this type of information about any new agent
involved in noninvasive imaging of patients who
have suspected or known coronary disease.
Regadenoson is a pharmacological stress agent
that recently received regulatory approval and has
quickly gained widespread use for radionuclide
MPI, due in part to its more convenient method of
administration compared with adenosine (i.e., bolus
dosing instead of the requirement for an infusion
pump) (9). In vivo studies support the belief that
regadenoson is more selective for the adenosine A2A
receptor than adenosine (10), which in theory
should make the adverse effect profile more favor-
able. The data on this point have been more mixed,
with composite scores in trials showing some ben-
efit over adenosine in that regard but prevalence of
individual adverse effects revealing little difference
(9). There is a growing literature on the safety of
using regadenoson in patients with chronic pulmo-
nary disease (11), which is clinically useful.
In this issue of iJACC, Iqbal et al. (12) report
results of 1 of the initial large-scale outcomes
studies on imaging with regadenoson; it is thus a
paper of great interest. The investigators assembled
a cohort of 1,000 consecutive patients from a single
center who underwent pharmacological stress with
this new agent and who also had normal perfusion
images and normal left ventricular function. All
patients were followed for 2 years after testing for
the occurrence of any composite of events, includ-
ing cardiac death, nonfatal myocardial infarction, or
revascularization. The results show that the rate of
the composite endpoint was low among these pa-
tients, and the rate of the “harder” endpoints ofcardiac death or nonfatal myocardial infarction was
also low and in the range of results reported in most
other studies of noninvasive imaging modalities.
This is important and clinically useful information.
Most papers reporting prognostic data for imag-
ing tests are descriptive of only 1 modality. The
paper by Iqbal et al. (12), however, also reports
comparative data on outcomes associated with nor-
mal adenosine pharmacological stress MPI in an-
other sample of 1,000 consecutive patients from the
same center, albeit from an earlier era before the
laboratory switched stress agents for everyday use.
The results show that the regadenoson data are
generally comparable to those of adenosine in terms
of the low risk associated with a normal perfusion
study result. This comparison is a major strength of
the paper and is of great interest. Such an analytical
approach brings with it significant challenges, how-
ever. As seen in Table 1 of the paper, there were
substantial demographic and clinical differences be-
tween the 2 patient groups. Among the adenosine
group, there was a much higher rate of inpatient
testing, likely a marker of a sicker, higher-risk
population. Among the regadenoson group, there
was a much higher rate of referral for testing for
pre-transplant evaluation, likely a marker of signif-
icant noncardiac morbidities. The investigators ad-
dressed this issue by using propensity scoring and
matching, creating a subcohort of the 2 groups well
matched for almost all characteristics, in which
the outcomes were compared. This analysis also
found that the prognostic value of a normal MPI
study result was similar between the 2 agents, in
a much “cleaner” comparison, albeit with fewer
patients and events and thus with lower confi-
dence in the estimates.
There are several strengths of this analysis (12).
As noted, few papers directly compare outcomes
associated with different imaging agents or tech-
niques. The authors’ use of propensity scoring and
matching to attempt to address the baseline differ-
ences in the population samples clearly sets a
standard for such analyses for the future.
There are also some important limitations to bear
in mind. Although the total group of 2,000 patients
reported seems large, by the time the groups are
“whittled down” in the propensity-matched co-
horts, there remains only approximately 500 pa-
tients per group, and, as noted earlier, the rate of
events is low (12). This leads to wide confidence
limits around the hazard ratio comparing regade-
noson with adenosine, and thus leaves open the
possibility that regadenoson is distinctly worse, or
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1024better, than adenosine with regard to the outcome
of interest, although that is not likely.
Moreover, reporting only outcomes associated
with a normal MPI study result, while of interest
and clinically useful, is an incomplete descriptor of
the prognostic power of a technique. It would have
been more informative to assemble cohorts of con-
secutive patients referred for testing and assessed
outcomes associated with the entire range of MPI
results, from normal to severely abnormal, as is
usually done. If, for instance, it was found that
outcomes associated with a mild or moderately
abnormal regadenoson MPI were also low risk (i.e.,
“false positive” with regard to prognosis), this find-
ing would have called into question the overall
impact of using this agent. Again, that finding is
not likely but remains an open question that needs
to be addressed.
Hence, the study by Iqbal et al. (12) is a stepEvaluatioN For Clinical Outcomes: 1993;71:865–7.stress agent. Their findings that outcomes associ-
ated with a normal regadenoson MPI study are
indeed low risk is important knowledge for clini-
cians making decisions about patient management
after testing. The use of propensity scoring and
matching to allow a direct comparison between a
well-established agent and a newer agent in this
field sets a standard for future comparative studies.
We will need to await future studies that assess the
outcomes associated with a full range of MPI results
with this agent and also involve large numbers of
patients beyond a highly expert single center. The
bar for outcomes studies is now very high, with
multicenter studies involving many thousands of
patients (7) becoming the norm.
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